Doxycycline
Small molecule targets MMP2, MMP9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VIBRAMYCIN | — | 1992-12-15 | fda.gov ↗ |
| Approved | US (FDA) | VIBRAMYCIN | — | 1967-12-06 | fda.gov ↗ |
Trials 227 · started per year
Also used as a comparator or background therapy in 159 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06414408 Comparator | Oct 2024 → Sep 2026 expected | bacterial sexually transmitted disease | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 0 | NCT05100654 Comparator | Apr 2022 → Dec 2027 expected | erectile dysfunction, prosthesis-related infectious disease | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05431673 Comparator | Aug 2022 → Jun 2023 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03435952 Background | Jul 2018 → Oct 2026 expected | breast cancer, cancer of unknown primary site, digestive system cancer, female reproductive organ cancer +7 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04206631 Comparator | Apr → Sep 2015 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT00783523 Comparator | Mar 2008 → Dec 2010 | arteriovenous hemangioma/malformation, brain aneurysm, cavernous hemangioma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00829790 Comparator | Oct 2006 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00829764 Comparator | Oct 2006 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00243893 Comparator | Jul 2004 → Oct 2008 | arteriovenous malformations of the brain, brain aneurysm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07180563 Background | Mar 2025 → Nov 2026 expected | chronic endometritis | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06329882 Comparator | Mar 2024 → Mar 2026 overdue | type 2 diabetes mellitus | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02036528 Background | Jan → Dec 2014 | ulcer of lower limbs | Royer Biomedical, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01301586 Comparator | Nov 2010 → Sep 2011 | acne | Nexgen Dermatologics, Inc. | Unknown | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT05216744 Background | Jul 2021 → Feb 2022 | chlamydia trachomatis infectious disease, gonorrhea | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2 | NCT04551755 Comparator | Sep → Nov 2020 | COVID-19 | Bangladesh Medical Research Council (BMRC) | Unknown | No outcome recorded |
| Phase 2 | NCT04407130 Comparator | Jun → Oct 2020 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT03508232 Comparator | Jan 2020 → Jul 2025 | ST-elevation myocardial infarction, heart failure | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT03986996 Comparator | Jul 2019 → May 2022 | ulcerative colitis | Wolfson Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03968562 Comparator | May 2019 → May 2022 | urticaria | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03397004 Comparator | Sep 2018 → Feb 2021 | hereditary hemorrhagic telangiectasia | Unity Health Toronto | Completed | No outcome recorded |
| Phase 2 | NCT03618108 Comparator | Apr 2018 → Nov 2020 | chlamydia infectious disease, coronary atherosclerosis | Cadrock Pty. Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02850913 Comparator | Sep 2016 → Apr 2020 | epilepsy | Makerere University | Unknown | No outcome recorded |
| Phase 2 | NCT02606032 Comparator | May 2016 → Jan 2021 | ulcerative colitis | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01756833 Comparator | May 2013 → Jul 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT01783860 Comparator | Jan → Jul 2013 | blepharitis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01594827 Background | Oct 2012 → Dec 2017 | cystic fibrosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01631617 Comparator | Sep 2012 → Jan 2027 expected | atopic eczema | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Recruiting | No outcome recorded |
| Phase 2 | NCT01867294 Comparator | Aug 2012 → May 2014 | metastatic malignant neoplasm, toxic dermatosis | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT01418742 Comparator | Aug 2011 → May 2013 | colorectal carcinoma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Terminated | No outcome recorded |
| Phase 2 | NCT01668498 Comparator | May 2011 → Jan 2015 | colorectal cancer | AIO-Studien-gGmbH | Completed | No outcome recorded |
| Phase 2 | NCT01320033 Comparator | Mar 2011 → Jan 2012 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT01243437 Comparator | Dec 2010 → Jun 2013 | plague | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT01160640 Comparator | Nov 2010 → Aug 2015 | pelvic inflammatory disease | Harold Wiesenfeld | Completed | No outcome recorded |
| Phase 2 | NCT00830401 Comparator | Jun 2007 → Nov 2008 | uterine anomalies | UMC Utrecht | Terminated | No outcome recorded |
| Phase 2 | NCT00439400 Comparator | Feb → Aug 2007 | dry eye syndrome | Alacrity Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00419848 Comparator | Aug 2006 → Jan 2008 | acne | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00066066 Comparator | Jul 2003 → Jul 2009 | periodontitis | The Forsyth Institute | Completed | No outcome recorded |
| Phase 2 | NCT00538967 Comparator | May 2002 → Aug 2005 | abdominal aortic aneurysm | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07202078 Background | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07202091 Background | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05972772 Comparator | Nov 2024 → Aug 2025 overdue | infectious disease | Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05897034 Comparator | Jun 2023 → Jun 2024 overdue | bacterial sexually transmitted disease | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05678621 Background | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02735837 Comparator | Jan 2015 → Mar 2016 | diabetes mellitus | Amirhossein Farahmand | Completed | No outcome recorded |
| Phase 2/3 | NCT02538224 Comparator | Jul 2013 → Feb 2014 | chronic periodontitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT06447480 Comparator | Apr 2025 → Sep 2026 expected | acne | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05398055 Background | May 2022 → Dec 2025 | Rocky mountain spotted fever | Hospital General de Mexicali | Unknown | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT05343455 Comparator | Mar 2022 → Jun 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05296629 Comparator | Mar 2022 → Jun 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04723940 Comparator | Jan 2021 → Jan 2023 | periprosthetic joint infection | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04523831 Comparator | Jun → Aug 2020 | COVID-19 | Dhaka Medical College | Completed | No outcome recorded |
| Phase 3 | NCT02929121 Comparator | Jan 2019 → Jun 2021 | filariasis, lymphedema | The Task Force for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT02927496 Comparator | Jun 2018 → Dec 2020 | filariasis, lymphedema | The Task Force for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT02929134 Comparator | Feb 2018 → Jun 2020 | filariasis, lymphedema | The Task Force for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT03334682 Comparator | Jan 2018 → Feb 2023 | acne | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02553473 Comparator | Oct 2015 → Jan 2020 | Lyme disease | Sorlandet Hospital HF | Completed | No outcome recorded |
| Phase 3 | NCT02305940 Comparator | Jul 2014 → Jul 2017 | chronic obstructive pulmonary disease | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT01931150 Background | Aug 2013 → Sep 2015 | acneiform dermatitis, cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01658995 Comparator | Sep 2012 → Dec 2019 | — | Petra M. Casey | Completed | No outcome recorded |
| Phase 3 | NCT01398072 Comparator | Dec 2011 → Jan 2013 | chronic obstructive pulmonary disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT01788215 Comparator | Nov 2010 → Sep 2014 | menstrual disorder, polycystic ovary syndrome | University of Rochester | Completed | No outcome recorded |
| Phase 3 | NCT01595594 Comparator | Mar 2010 → Apr 2012 | periodontal disorder, type 2 diabetes mellitus | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT02220751 Comparator | Mar 2009 → Sep 2011 | periodontitis, type 2 diabetes mellitus | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00688064 Background | Aug 2008 → Feb 2009 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00715858 Comparator | May 2008 → Aug 2009 | Alzheimer disease | McMaster University | Unknown | No outcome recorded |
| Phase 3 | NCT01254799 Comparator | Jan 2008 → Sep 2010 | uterine disorder | Omar Mamdouh Shaaban | Completed | No outcome recorded |
| Phase 3 | NCT00358462 Comparator | Jan 2007 → Nov 2011 | urethritis | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00351273 Comparator | May 2006 → Sep 2008 | reactive arthritis | University of South Florida | Completed | No outcome recorded |
| Phase 3 | NCT00138801 Comparator | Mar 2004 → Mar 2008 | Lyme disease | Sorlandet Hospital HF | Completed | No outcome recorded |
| Phase 3 | NCT00031499 Comparator | Jun 2000 → Aug 2007 | syphilis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 443 trials | ||||||
| Phase 4 | NCT07634341 Comparator | Jun 2026 → Jun 2027 expected | chronic periodontitis | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07230028 Background | Mar → Nov 2026 expected | infectious disorder of the nervous system | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06468462 Comparator | Oct 2025 → Oct 2028 expected | gonorrhea, syphilis | University of Washington | Recruiting | No outcome recorded |
| Phase 4 | NCT07164131 Comparator | Sep 2025 → Sep 2030 expected | pneumonia | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06188442 Comparator | Mar 2025 → Dec 2027 expected | chlamydia trachomatis infectious disease, gonorrhea, syphilis | Chinese University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07357337 Comparator | Feb → Aug 2025 | acne | Ghurki Trust and Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06422221 Comparator | Jul 2024 → Jan 2025 | bacterial infectious disease, endocarditis | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05853120 Comparator | May 2023 → Sep 2024 | sexually transmitted disease | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT05980871 Comparator | Mar 2023 → Jul 2025 | syphilis | National Taiwan University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT04864717 Comparator | Sep 2021 → Dec 2022 | acneiform dermatitis, cancer-related condition | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 4 | NCT05040334 Comparator | Jan 2021 → Apr 2022 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04729140 Comparator | Dec 2020 → Dec 2021 | COVID-19 | Max Health, Subsero Health | Unknown | No outcome recorded |
| Phase 4 | NCT04297592 Comparator | Jun 2020 → Jan 2027 expected | autoimmune disease, chronic kidney disease, diabetes mellitus, methicillin-resistant staphylococcus aureus infectious disease +3 | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04239755 Comparator | Feb → Jul 2020 | traumatic brain injury | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT03479502 Comparator | Mar 2018 → Feb 2022 | frozen shoulder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03162497 Comparator | Jan 2018 → Sep 2022 | dry eye syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT03083197 Comparator | Oct 2017 → Oct 2026 expected | scrub typhus | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02913118 Background | Jul 2016 → Jan 2019 | — | Qingfeng Pharmaceutical Group | Unknown | No outcome recorded |
| Phase 4 | NCT03765931 Comparator | Jul 2016 → Jan 2017 | — | Research Institute for Development | Completed | No outcome recorded |
| Phase 4 | NCT02623959 Comparator | Apr 2016 → May 2017 | high grade malignant neoplasm, pleural neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 4 | NCT02553083 Comparator | Oct 2015 → Sep 2020 | Helicobacter pylori infectious disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01885910 Background | Jul 2013 → Jul 2014 | acne | Derm Research, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT01825408 Comparator | Feb 2013 → Jun 2014 | sinusitis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT01879930 Comparator | Nov 2012 → Mar 2015 | chronic pain syndrome, urinary bladder disorder | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 4 | NCT01368341 Comparator | Jun 2011 → Dec 2013 | Borrelia infectious disease, Lyme disease | Morten Lindbaek | Completed | No outcome recorded |
| Phase 4 | NCT01308619 Comparator | Apr 2011 → Aug 2012 | rosacea | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01207739 Comparator | Sep 2010 → Oct 2013 | Borrelia infectious disease, Lyme disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01014260 Comparator | Sep 2010 → Mar 2011 | cardiovascular disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02487186 Comparator | Mar 2010 → Dec 2014 | periodontal disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01661985 Comparator | Feb 2010 → Aug 2015 | Mycoplasmoides infection, cervicitis, chlamydia trachomatis infectious disease, urethritis | Ostergotland County Council, Sweden | Unknown | No outcome recorded |
| Phase 4 | NCT00952861 Comparator | Oct 2009 → Oct 2010 | chronic obstructive pulmonary disease | Odense University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT00989742 Comparator | Jul 2009 → Jan 2013 | lung lymphangioleiomyomatosis, tuberous sclerosis | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT00855595 Background | Feb → Apr 2009 | rosacea | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00803452 Comparator | Jul 2008 → Dec 2010 | blepharitis | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT00837213 Comparator | Aug 2007 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00495313 Comparator | Mar → Dec 2007 | rosacea | CollaGenex Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01518192 Comparator | Jun 2006 → Nov 2007 | post-treatment Lyme disease syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT00376493 Comparator | May 2006 → Dec 2007 | uterine disorder | Hospital de Clinicas de Porto Alegre | Terminated | No outcome recorded |
| Phase not applicable42 trials | ||||||
| — | NCT07032506 Background | May 2026 → Sep 2029 expected | adhesions of uterus | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| — | NCT07361926 Comparator | May 2026 → Jun 2029 expected | HIV infectious disease | University of Washington | Not yet recruiting | No outcome recorded |
| — | NCT06915688 Comparator | Apr → Jul 2025 overdue | chronic obstructive pulmonary disease | Amina Aslam | Not yet recruiting | No outcome recorded |
| — | NCT06412588 Comparator | Jun 2024 → Jan 2026 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| — | NCT07488949 Comparator | Apr 2024 → Dec 2030 expected | chronic endometritis | Fang Wang | Recruiting | No outcome recorded |
| — | NCT06069141 Comparator | Jan 2024 → Dec 2027 expected | latent early syphilis | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT07513103 Comparator | Sep 2022 → Jun 2024 | scrub typhus | Jin Soo Lee | Completed | No outcome recorded |
| — | NCT05268120 Comparator | Jul 2022 → May 2028 expected | methicillin-resistant staphylococcus aureus infectious disease | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT05191875 Background | Dec 2021 → Apr 2022 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| — | NCT05410223 Background | Apr 2021 → Dec 2022 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT03194204 Comparator | Oct 2019 → Feb 2020 | rheumatoid arthritis | Assiut University | Completed | No outcome recorded |
| — | NCT05445362 Comparator | Feb 2019 → Aug 2020 | — | Reham Hassan | Completed | No outcome recorded |
| — | NCT03824340 Comparator | Jan → Nov 2019 | female infertility | Aljazeera Hospital | Unknown | No outcome recorded |
| — | NCT03462329 Comparator | Jun 2018 → Dec 2028 expected | — | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT03337932 Comparator | May 2018 → Dec 2027 expected | — | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03153267 Comparator | Jun 2017 → Dec 2019 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02756403 Comparator | Mar 2016 → Jul 2017 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| — | NCT03585140 Background | Jan → May 2016 | acne | Centro Dermatológico Dr. Ladislao de la Pascua | Completed | No outcome recorded |
| — | NCT03115177 Comparator | Nov 2015 → Feb 2017 | osteoarthritis | Rush University Medical Center | Completed | No outcome recorded |
| — | NCT02688738 Comparator | Mar 2015 → Dec 2016 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT01744093 Comparator | Dec 2014 → Jun 2017 | HIV infectious disease, pulmonary emphysema | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT03956446 Comparator | Sep 2014 → Dec 2027 expected | tick-borne encephalitis | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT02463942 Comparator | Sep 2014 → Sep 2020 | tick-borne encephalitis | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT02845024 Comparator | Sep 2014 → Dec 2015 | diabetes mellitus | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| — | NCT02204254 Comparator | Mar 2014 → Apr 2018 | rosacea | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| — | NCT02147262 Comparator | Jul 2013 → Jul 2020 | acrodermatitis chronica atrophicans | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT01469585 Comparator | Nov 2011 → May 2012 | — | University of Hawaii | Completed | No outcome recorded |
| — | NCT01163994 Comparator | Jun 2010 → Oct 2017 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT01198509 Comparator | Jan 2010 → Jan 2013 | periodontal disorder, psoriatic arthritis | NYU Langone Health | Completed | No outcome recorded |
| — | NCT01188954 Comparator | Jan 2010 → Nov 2012 | — | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT00942006 Comparator | Jul 2009 → Nov 2010 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT00910715 Comparator | Jun 2009 → Nov 2010 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT01112059 Comparator | Nov 2008 → Nov 2012 | cystic fibrosis | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00639873 Comparator | Jun 2008 → Nov 2009 | malaria | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00568711 Comparator | Sep 2006 → Dec 2009 | scrub typhus | Dong-Min Kim | Completed | No outcome recorded |
| — | NCT01049438 Background | Aug 2006 → Sep 2009 | methicillin-resistant staphylococcus aureus infectious disease | Natividad Medical Center | Completed | No outcome recorded |
| — | NCT03584919 Comparator | Jun 2006 → Sep 2007 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT00353743 Comparator | May 2006 → Nov 2007 | — | Hospital de Clinicas de Porto Alegre | Terminated | No outcome recorded |
| — | NCT01205464 Comparator | Feb 2005 → Feb 2008 | cognitive disorder, palsy, radiculopathy | Linkoeping University | Completed | No outcome recorded |
| — | NCT01842100 Comparator | Sep 1999 → Feb 2006 | pelvic inflammatory disease, sexually transmitted disease | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT02388477 Comparator | ? → May 2016 | rotator cuff syndrome | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 391 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxycycline | “Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to...” NCT01730352 ↗367“Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher,...” NCT00332163 ↗ “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗ “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “patients will receive LOAD therapy comprising of levofloxacin (250 mg with breakfast), omeprazole (40 mg before breakfast), nitazoxanide (Alina) (500 mg twice daily with meals)...” NCT06050824 ↗ “This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of...” NCT05411484 ↗ “Group3: (110) participants received Levofloxacin quadruple regimen (LOAD) in the form of nitazoxanide 500 mg bid, levofloxacin 250 mg QD, omeprazole 40 mg QD, and doxycycline...” NCT04039412 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix metalloproteinase-2-induced troponin I cleavage in rat hearts and improved contractile function following...” PMID 23928836 ↗ Nov 2013 “Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours...” NCT06188442 ↗ “per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a...” NCT04447625 ↗ “per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a...” NCT05205993 ↗ “Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days” NCT01113931 ↗ “A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small cell Lung Cancer After Failure of First Line Chemotherapy” NCT00531934 ↗ “When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.” NCT04211649 ↗ “Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.” NCT02487186 ↗ “100 mg of oral doxycycline twice daily or other appropriate antibiotic in allergic patients to be given while the intrauterine stent is in place” NCT07032506 ↗ “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses.” NCT05072093 ↗ “Doxycycline (Vibramycin, 100-mg film-coated tablets; Pfizer)) 200-mg loading dose, followed by 100 mg every 12 hours for 3 days.” NCT05972772 ↗ “topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d” NCT06447480 ↗ “Doxycycline exhibits anti-inflammatory properties, suggesting potential benefit as an adjunctive therapy in T2DM.” PMID 42271067 ↗ Jun 2026 “Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.” NCT01245946 ↗ “D-PLEX is a new formulation of extended controlled release of Doxycycline in the applied area for about 30 days.” NCT03633123 ↗ “all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion” NCT01842100 ↗ “oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)” NCT01931150 ↗ “Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated.” NCT05897034 ↗ “Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.” NCT05678621 ↗ “The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline .” NCT05445362 ↗ “Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.” NCT02257658 ↗ “Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days” NCT05184491 ↗ “Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.” NCT07202091 ↗ “Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.” NCT07202052 ↗ “Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole” NCT07202078 ↗ “trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days” NCT01232231 ↗ “Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.” NCT00688064 ↗ “D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)” NCT03558984 ↗ “If penicillin allergic, Doxycycline 100mg every 12 hours until the EVD is removed.” NCT05001750 ↗ “Group A: Will receive oral doxycycline in a dose of 200 mg daily for three months.” NCT03454945 ↗ “Oral doxycycline administered for treatment of suspected or confirmed plague.” NCT01243437 ↗ “PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks” NCT02033408 ↗ “Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine” NCT02366884 ↗ “Third group are Type 2 DM patients who received doxycycline 20mg twice/day.” NCT06199440 ↗ “D-PLEX is a new formulation of extended controlled release Doxycycline.” NCT02731573 ↗ “Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days” NCT04591600 ↗ “a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)” NCT05040334 ↗ “comparing weekly Isotretinoin to daily Doxycycline over four months.” NCT06225570 ↗ “D-PLEX is a new formulation of extended release of Doxycycline.” NCT04233424 ↗ “D-PLEX is a new formulation of extended release of Doxycycline.” NCT04411199 ↗ “Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt)” NCT03533231 ↗ “local antibiotics (10% doxycycline) into periodontal pockets” NCT07027137 ↗ “ORACEA® (40mg doxycycline) capsule daily for 24 months” NCT01782989 ↗ “DEC 300 mg + Doxycycline 100 mg coadministration” PMID 26691247 ↗ Jun 2015 “Oral doxycycline 100mg uid, for study duration.” NCT02201381 ↗ “preventive antibiotic (doxycycline) for STIs” NCT07361926 ↗ “doxycycline orally, 100 mg, bid, 14 days” NCT02147249 ↗ “* Doxycycline PO 200mg once daily” NCT02123628 ↗ “Doxycycline daily dosing (100mg)” NCT04584567 ↗ “doxycycline (Doxybene) 200mg” NCT06710600 ↗ “Drug: Doxycycline” NCT04626193 ↗ “Doxycycline” NCT02099240 ↗ “doxycycline” NCT01049438 ↗ |
| Known as | Adoxa | “Mylan's doxycycline monohydrate 100 mg tablets to Par's Adoxa® 100 mg tablets” NCT00649571 ↗1“Adoxa Tablets 100 mg” NCT00648180 ↗ |
| Known as | ALTY-0501 | “ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution)” NCT00439400 ↗ |
| Known as | Atridox 10% | “doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket” NCT05875506 ↗ |
| Known as | Bassado | “tablets of DOXY hydrocloride (Bassado)” NCT04846335 ↗ |
| Known as | CASnr 564-25-0 (doxycycline); 17086-28-1 (doxycycline monohydraat) | “CASnr 564-25-0 (doxycycline); 17086-28-1 (doxycycline monohydraat)” NCT01207739 ↗ |
| Known as | D-PLEX | “D-PLEX is a new formulation of extended controlled release Doxycycline.” NCT02731573 ↗ |
| Known as | Dexxon | “either doxycycline (Dexxon, in a dose of 200 mg the first day and then 100 mg per day for four days) or placebo after presumed exposure to TBRF” PMID 16837678 ↗ Jul 2006 |
| Known as | DOX | “Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug...” NCT04860505 ↗4“a single 1 g intravenous (IV) dose of ceftriaxone (CRO) plus doxycycline (DOX) versus a single 800 mg oral dose of cefixime (CFM) plus DOX for the treatment of NG-CT co-infection” PMID 35810277 ↗ Jul 2022 “Doxycycline (DOX) is an inexpensive, FDA approved antibiotic that inhibits MMPs and reduces nitric oxide synthesis.” NCT00064766 ↗ “Doxycycline (DOX) has been proven in vitro to inhibit MMP-mediated degradation of stromal matrix.” PMID 22325113 ↗ Feb 2012 “Doxycycline (DOX) is a potent MMP inhibitor.” NCT01375491 ↗ |
| Known as | Doxy | “doxycycline (Doxy) disrupts amyloid fibrils in vitro and in animal models synergistically with tauroursodeoxycholic acid (TUDCA).” NCT03481972 ↗ |
| Known as | Doxybene | “doxycycline (Doxybene) 200mg” NCT06710600 ↗ |
| Known as | Doxycap. Registration No: MAL 19921000A | “Doxycap. Registration No: MAL 19921000A” NCT04234945 ↗ |
| Known as | Doxycyclin | “Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin” NCT03491995 ↗7“•Doxycyclin, amoxicillin and metronidazole” NCT02345733 ↗ “Doxycyclin, amoxicillin and metronidazole” NCT02217722 ↗ “* Doxycyclin : 200mg/day” NCT05074147 ↗ |
| Known as | Doxycycline Anhydrous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03457636 ↗ |
| Known as | Doxycycline Capsule | “Drug: Doxycycline Capsule” NCT06069141 ↗ |
| Known as | Doxycycline Hcl | “Drug: Doxycycline Hcl” NCT04846335 ↗ |
| Known as | doxycycline hyclate | “Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of...” NCT03608774 ↗11“doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket” NCT05875506 ↗ “All eligible subjects will receive doxycycline hyclate (100 mg twice daily) as well as TUDCA 250 mg three times a day orally.” NCT01855360 ↗ “Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years” NCT00066027 ↗ “doxycycline PEP (doxycycline hyclate, 200 mg taken within 72 hours after condomless sex)” PMID 38118022 ↗ Dec 2023 “Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.” NCT00688064 ↗ “Doxycycline Hyclate capsules, USP 50 mg” NCT04504123 ↗ “doxycycline hyclate 20 mg twice daily” NCT00041977 ↗ “Doxycycline hyclate (Doryx)” NCT00635609 ↗ “Drug: Doxycycline Hyclate” NCT03508232 ↗ “Drug: Doxycycline Hyclate” NCT03397004 ↗ “Drug: Doxycycline Hyclate” NCT04762134 ↗ |
| Known as | doxycycline hydrochloride | “11After hysteroscopic diagnosis of chronic endometritis, patients received monotherapy with doxycycline hydrochloride capsules for 14 days.” NCT07180563 ↗ |
| Known as | doxycycline monohydrate | “Nanodox 1% (doxycycline monohydrate hydrogel)” NCT02910011 ↗8“NanoDOX 1% doxycycline monohydrate Hydrogel” NCT01547325 ↗ “Doxycycline Monohydrate Tablets (100 mg” NCT00649571 ↗ “Doxycycline Monohydrate Tablets 100 mg” NCT00648180 ↗ |
| Known as | Doxycycline Monohydrate USP | “NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser” NCT05411484 ↗ |
| Known as | Doxycycline Sandoz | “(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months” NCT03334682 ↗ |
| Known as | Doxycycline Tablets | “Drug: Doxycycline Tablets” NCT03194204 ↗ |
| Known as | Doxycycline-Doxylin | “Doxycycline-Doxylin®” NCT02033408 ↗ |
| Known as | Doxycyline | “Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.” NCT00830401 ↗ |
| Known as | NanoDOX | “Nanodox 1% (doxycycline monohydrate hydrogel)” NCT02910011 ↗1“NanoDOX 1% doxycycline monohydrate Hydrogel” NCT01547325 ↗ |
| Known as | Oracea | “ORACEA® (40mg doxycycline) capsule daily for 24 months” NCT01782989 ↗ |
| Known as | Oraycea | “Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.” NCT03340961 ↗ |
| Known as | Periostat | “The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting...” NCT00246740 ↗ |
| Known as | Periostat(R) | “The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and...” NCT00041977 ↗ |
| Known as | tetracycline | “doxycycline (tetracycline)” NCT07320001 ↗ |
| Known as | Vibramycin | “Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days” NCT01113931 ↗1“Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt)” NCT03533231 ↗ |
| Known as | Zadorin-100 (doxycycline), licence number Swissmedic: 43051 | “Zadorin-100® (doxycycline), licence number Swissmedic: 43051” NCT01879930 ↗ |
| Action | Inhibit | “inhibits MMPs” NCT00064766 ↗ |
| Modality | Small molecule | “These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases” NCT00243893 ↗ |
| Route | Oral | “Doxycycline HCI 10mg po for 2 weeks” NCT00012688 ↗ |
| Target | MMP9 | “MMP-9 inhibiting properties” NCT00538967 ↗ |